A paclitaxel prodrug nanoparticles with glutathion/reactive oxygen species dual‐responsive and CD206 targeting to improve the anti‐tumour effect

A paclitaxel prodrug nanoparticles with glutathion/reactive oxygen species dual‐responsive and CD206 targeting to improve the anti‐tumour effect

Abstract As a first‐line anticancer drug, paclitaxel has shortcomings, such as poor solubility and lack of tumour cell selectivity, which limit its further applications in clinical practice. Therefore, the authors aimed to utilise the characteristics of prodrug and nanotechnology to prepare a reacti...

Full description

Bibliographic Details
Main Authors: Changhai Wang, Yuwen Jiao, Xinyu Zhang, Mingxue Guo, Qing Zhang, Wenjun Hu, Shuang Dong, Tangthianchaichana Jakkree, Yang Lu, Jinling Wang
Format: Article
Language:English
Published: Hindawi-IET 2023-07-01
Series:IET Nanobiotechnology
Subjects:
cellular effects of radiation
drugs
drug delivery systems
nanoparticle
tumours
Online Access:https://doi.org/10.1049/nbt2.12119

Internet

https://doi.org/10.1049/nbt2.12119

Similar Items